On the stock market since 2014, it operates in the world of health and science. It has 3,103 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Revenue is spread across several lines; no single product carries the company.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 96% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $3.0B a year; the problem isn’t sales — it’s costs running above that number.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
The average analyst price target is $2.00 — 434% above today’s price.
A loss of $569.1M against $3.0B in annual sales.
The stock sits at $0.37. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, ENDP sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ENDP has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.